Hepatitis B virus core protein as an epitope vaccine carrier: a review

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 26, Issue 4, 2010, Pages 431-438

  Yin, Ying ^a   Xu, Junjie ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Epitope vaccine; Gene recombination; Hepatitis B virus core protein; Vaccine carrier

Indexed keywords

DRUG CARRIER; EPITOPE; HEPATITIS B CORE ANTIGEN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

BIOSYNTHESIS; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW;

ADJUVANTS, IMMUNOLOGIC; DRUG CARRIERS; EPITOPES; GENETIC VECTORS; HEPATITIS B CORE ANTIGENS; HUMANS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

HEPATITIS B VIRUS;

EID: 77954813062     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology, 2001, 44(2/3): 98-114.
2. Pumpens P, Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett, 1999, 442(1): 1-6.
3. Riedl P, Stober D, Oehninger C, et al. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol, 2002, 168(10): 4951-4959.
4. Broos K, Janssens ME, De Goeyse I, et al. Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit. Clin Vaccine Immunol, 2008, 15(5): 852-858.
5. Lee KW, Tan WS. Recombinant hepatitis B virus core particles: association, dissociation and encapsidation of green fluorescent protein. J Virol Methods, 2008, 151(2): 172-180.
6. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol Cell, 1999, 3(6): 771-780.
7. Crowther RA, Kiselev NA, Bottcher B, et al. Threedimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell, 1994, 77(6): 943-950.
8. Roseman AM, Berriman JA, Wynne SA, et al. A structural model for maturation of the hepatitis B virus core. Proc Natl Acad Sci USA, 2005, 102(44): 15821-15826.
9. Zlotnick A, Cheng N, Conway JF, et al. Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry, 1996, 35(23): 7412-7421.
10. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine, 2002, 20(25/26): 3104-3112.
11. Borisova GP, Kalis IaV, Pushko PM, et al. Genetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assembly. Dokl Akad Nauk SSSR, 1988, 298(6): 1474-1478.
12. Gallina A, Bonelli F, Zentilin L, et al. A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids. J Virol, 1989, 63(11): 4645-4652.
13. Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol, 1990, 64(7): 3319-3330.
14. Billaud J N, Peterson D, Barr M, et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol, 2005, 79(21): 13656-13666.
15. De Filette M, Min JW, Birkett A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology, 2005, 337(1): 149-161.
16. De Filette M, Fiers W, Martens W, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine, 2006, 24(44/46): 6597-6601.
17. Han JF, Wu YZ. HBcAg virus like particles and vaccine design. Immunol J, 2005, 21(3): 17-19.
18. Yin Y, Zhang J, Dong DY, et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis. Vaccine, 2008, 26: 5814-5821.
19. Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA, 1999, 96(5): 1915-1920.
20. Nassal M, Skamel C, Vogel M, et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int J Med Microbiol, 2008, 298(1/2): 135-142.
21. Zhang YL, Guo YJ, Wang KY, et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus. Scand J Immunol, 2007, 65(4): 320-328.
22. Karpenko LI, Ivanisenko VA, Pika IA, et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids, 2000, 18(4): 329-337.
23. Schotsaert M, De Filette M, Fiers W, et al. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines, 2009, 8(4): 499-508.
24. Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med, 1999, 5(10): 1157-1163.
25. Fiers W, De Filette M, Birkett A, et al. A "universal" human influenza A vaccine. Virus Res, 2004, 103(1/2): 173-176.
26. Gregson AL, Oliveira G, Othoro C, et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One, 2008, 3(2): e1556.
27. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun, 2004, 72(11): 6519-6527.
28. Walther M, Dunachie S, Keating S, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine, 2005, 23(7): 857-864.
29. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun, 2005, 73(6): 3587-3597.
30. Zhang Y, Song S, Liu C, et al. Generation of chimeric HBc proteins with epitopes in E. coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cell Immunol, 2007, 247(1): 18-27.
31. Song S, Wang Y, Zhang Y, et al. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG. Cancer Lett, 2007, 256(1): 90-100.
32. Ma Y, Hayglass KT, Becker AB, et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy, 2007, 62(6): 675-682.
33. Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 2008, 26(2): 201-214.
34. De Filette M, Martens W, Smet A, et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine, 2008, 26(51): 6503-6507.